Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung Cancer

NCT05979623 | Completed

• 1 other identifier: B2021-128
• Study Type: observational
• Target: 971
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this observation study is to learn about clinicopathological characteristics and prognostic factors of stage IB NSCLC. The main question it aims to answer is wheather there is relationship between newly proposed clinicopathological features and the prognosis of stage IB NSCLC .The postoperative pathological and follow-up information of participants will be used for subsequent analysis.

Conditions

Stage IB Non-Small Cell Lung Carcinoma

Outcome Measures

Primary Outcomes (1)

• RFS

  recurrence-free survival

  5 years

Secondary Outcomes (1)

• OS

  5 years

Study Arms (1)

ZS-IB-NSCLC

A total of 971 NSCLC patients with pathological stage IB resected by surgery (R0) from January 2016 to December 2020 at Zhongshan Hospital of Fudan University

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

NSCLC patients with pathological stage IB resected by surgery (R0)

You may qualify if:

• It was confirmed by histopathology as primary non-small cell lung cancer, and the pathological type was LUSC or LUAD;
• According to the 8th edition of TNM clinical staging standards, it is determined as IB stage
• No treatment was performed for the primary lesion of lung cancer before surgery;
• No history of other malignant tumors before surgery;
• Detailed clinical and pathological information, complete survival data, and no missing follow-up data.

You may not qualify if:

• The postoperative histopathological types include non-scale and non adenocarcinoma, such as lung adenosquamous cell carcinoma, large cell lung cancer, or lung sarcomatoid carcinoma;
• Multiple lesion staging surgery;
• History of merging with other malignant tumors
• Having preoperative treatment;
• Missing follow-up information.

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead

Study Sites (1)

180 Fenglin Road

Shanghai, 200032, China

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Di Ge, Ph.D;M.D

  Zhongshan Hospital, Fudan University, Shanghai, China

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 29, 2023
• First Posted: August 7, 2023
• Study Start: January 1, 2016
• Primary Completion: December 1, 2020
• Study Completion: December 1, 2022
• Last Updated: August 7, 2023

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)